Syngene International Ltd Q3 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/knm6tdbawnorrx059k6ndgc1.pdf

Key Takeaways


Revenue Performance & Segment Mix


Stelis Biologics Facility Acquisition

Hunt: "we concluded the acquisition of the multi-modal biologics manufacturing facility from Stelis Biopharma Ltd and we have embarked on repurposing the facility from vaccines to biologics manufacturing in preparation for revalidation. We expect the facility to be ready for operations in the second half of fiscal year 2025, subject to regulatory approvals."

Margin & Cost Structure


Demand Environment & Biotech Funding


Balance Sheet & Investment Funding

Biswas: "With strong operating cash flows, we expect these investments to be funded by internal accruals."

Guidance & Commitments

CommitmentSpecificsTimeline
Full-year revenue growthAround double digits in constant currency (downgraded from mid-teens)FY24
Stelis facility operationalReady for operations, subject to regulatory approvalsSecond half of FY25
Investment fundingFunded by internal accruals with strong operating cash flowsOngoing

Key Metrics

MetricQ3 FY24
Revenue from operations₹854 crores, up 9% YoY
Reported revenue₹883 crores, up 10% YoY
Reported EBITDA₹261 crores, up 5% YoY
EBITDA margin30%, vs 31% in Q3 FY23
EBITDA from operations margin27%, vs 29% in Q3 FY23, -226bps
EBIT from operations margin14%, vs 17% in Q3 FY23, -288bps
PAT before exceptional items₹115 crores, up 4% YoY
PAT margin13%, vs 14% in Q3 FY23
PAT after exceptional items₹112 crores, up 2% YoY
Revenue from operations 9M FY24₹2,572 crores, up 17% YoY
PAT before exceptional items 9M FY24₹330 crores, up 16% YoY
Full-year revenue growth guidancearound double digits in constant currency, revised from mid-teens constant currency growth
Stelis acquisition revised gross value₹617 crores, adjusted from earlier gross value of ₹702 crores
Stelis facility biologics drug substance capacity addition20,000 litres, expected operational in second half of FY25 subject to regulatory approvals
Exceptional item (net of tax)3 crore, transaction costs relating to acquisition of Stelis Biopharma facility